BillionToOne will release its Q2 2026 financial results on August 5 and host a conference call.
Quiver AI Summary
BillionToOne, Inc., a molecular diagnostics company based in Menlo Park, California, announced that it will release its financial results for the second quarter of 2026 after the market closes on August 5, 2026. Following the release, the company will host a conference call at 1:30 PM Pacific Time to discuss the results, and participants are encouraged to register in advance. A live and archived webcast of the call will be available on the company's investor relations website. BillionToOne is dedicated to developing accessible and accurate diagnostic tests using its patented Quantitative Counting Templates™ technology, which allows for precise counting of DNA molecules.
Potential Positives
- BillionToOne is scheduled to release its financial results for Q2 2026, suggesting transparency and engagement with investors.
- The company will host a conference call to discuss the financial results, providing an opportunity for direct communication with analysts and investors.
- The use of the patented Quantitative Counting Templates™ (QCT™) technology positions BillionToOne as a leader in the molecular diagnostics field, highlighting its innovative capabilities.
Potential Negatives
- Announcement of upcoming financial results without any prior performance metrics may indicate a lack of transparency regarding current financial health.
- Hosting a conference call for financial results suggests that the company is possibly anticipating challenging questions from analysts about its performance.
FAQ
When will BillionToOne release its financial results?
BillionToOne plans to release its financial results for Q2 2026 on August 5, 2026, after market close.
What time is the BillionToOne conference call?
The conference call will take place at 1:30 PM Pacific Time / 4:30 PM Eastern Time on August 5, 2026.
How can analysts participate in the conference call?
Analysts should register before the call starts at 1:30 PM Pacific Time on August 5, 2026.
Where can I listen to the BillionToOne conference call?
A live and archived webcast of the call will be available on the investor relations website's “Events” page.
What is BillionToOne's core technology?
BillionToOne's core technology is the patented Quantitative Counting Templates™ (QCT™), which counts DNA molecules at the single-molecule level.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BLLN Insider Trading Activity
$BLLN insiders have traded $BLLN stock on the open market 73 times in the past 6 months. Of those trades, 0 have been purchases and 73 have been sales.
Here’s a breakdown of recent trading of $BLLN stock by insiders over the last 6 months:
- OGUZHAN ATAY (Chairman and CEO) has made 0 purchases and 42 sales selling 90,000 shares for an estimated $10,097,100.
- SHAN RIKU SAKAKIBARA (Chief Product Officer) has made 0 purchases and 9 sales selling 24,000 shares for an estimated $2,665,800.
- DAVID TSAO (Chief Technology Officer) has made 0 purchases and 11 sales selling 20,000 shares for an estimated $2,045,325.
- NANCY JOANN JOHNSON (See Remarks) has made 0 purchases and 8 sales selling 14,801 shares for an estimated $1,502,595.
- BOSCH JOHN RODERICK TEN (SVP of Laboratory Operations) has made 0 purchases and 3 sales selling 4,248 shares for an estimated $457,283.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BLLN Hedge Fund Activity
We have seen 52 institutional investors add shares of $BLLN stock to their portfolio, and 35 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAMCO INC /NY/ added 571,485 shares (+336.2%) to their portfolio in Q1 2026, for an estimated $45,113,025
- PRICE T ROWE ASSOCIATES INC /MD/ added 252,235 shares (+52.0%) to their portfolio in Q1 2026, for an estimated $19,911,430
- CITADEL ADVISORS LLC removed 148,868 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $11,751,639
- WASATCH ADVISORS LP added 148,446 shares (+40.2%) to their portfolio in Q2 2026, for an estimated $17,810,551
- PENN CAPITAL MANAGEMENT COMPANY, LLC added 126,335 shares (+inf%) to their portfolio in Q1 2026, for an estimated $9,972,884
- AMERIPRISE FINANCIAL INC added 97,762 shares (+80.0%) to their portfolio in Q1 2026, for an estimated $7,717,332
- UBS GROUP AG added 90,005 shares (+284.8%) to their portfolio in Q1 2026, for an estimated $7,104,994
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BLLN Analyst Ratings
Wall Street analysts have issued reports on $BLLN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 05/07/2026
To track analyst ratings and price targets for $BLLN, check out Quiver Quantitative's $BLLN forecast page.
$BLLN Price Targets
Multiple analysts have issued price targets for $BLLN recently. We have seen 4 analysts offer price targets for $BLLN in the last 6 months, with a median target of $125.0.
Here are some recent targets:
- Subbu Nambi from Guggenheim set a target price of $125.0 on 06/29/2026
- Mark Massaro from BTIG set a target price of $130.0 on 05/07/2026
- Casey Woodring from JP Morgan set a target price of $125.0 on 05/07/2026
- Brandon Couillard from Wells Fargo set a target price of $90.0 on 03/05/2026
Full Release
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, August 5, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested listeners will be available on the “Events” page of BillionToOne’s investor relations website at https://investors.billiontoone.com/ .
About BillionToOne
Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com .
Investor Contact
[email protected]
Media Contact
[email protected]
